Glucobrassicin-Brussel Sprout Effect on D10 Phe Metabolism

Study summary

To determine whether glucobrassicin-rich Brussels sprouts can favorably modify the metabolism of the polycyclic aromatic hydrocarbon deuterated phenanthrene (\[D10\]phe) in current and former smokers

Ask AI to explain this study

Start here

Key things to know

Main goalBasic Science

This describes the study’s primary purpose.

What is being studiedBrussel Sprouts and Deuterated Phenanthrene

The study team can explain what participation involves.

Who it may be forSmoking

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 17, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Masonic Cancer Center, University of Minnesota

Study sponsor

Study overview

What this study is about

Purpose: Basic Science
Study type: Interventional
Phase: Phase 1
Sponsor: Masonic Cancer Center, University of Minnesota
Interventions being studied: Other: Brussel Sprouts; Drug: Deuterated Phenanthrene

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Adult ≥ 18 years old
Current or former smoker by self-report
Willing to abstain from cruciferous vegetable consumption other than the study vegetable during the study period
Able to understand the experimental nature of the study and provide informed consent
Negative urine pregnancy test for women of childbearing potential within 7 days of baseline \[D10\]phe dosing

Reasons someone may not be able to joinExclusion criteria

Chronic proton pump inhibitor, H2-blocker (i.e., ranitidine, famotidine), and/or calcium carbonate use
History of gastric bypass surgery, gastric banding, bowel resection, malabsorption syndromes such as celiac sprue or pancreatic insufficiency, or other conditions that may affect gastric absorption
Current use of tobacco products other than cigarettes (i.e. snuff, snuz, smokeless tobacco, cigars, pipes) or use of these products within 3 months of study registration
Major or chronic medical disease, including heart disease, poorly controlled diabetes, etc., to be adjudicated by the principal investigator
Women who are pregnant, intend to become pregnant within 3 months of the study period, or who are breastfeeding
Current or recent (within 12 months) problems with drug use or alcohol dependence by self-report Antibiotic use within 2 months of study enrollment or during the study by self-report Alcohol dependence, abuse, or history of dependence/abuse by self-report Vegetarians
History of respiratory tract cancer
Use of metronidazole or antabuse during the study
Taking ibuprofen, naproxen, other NSAIDs, steroids (except inhaled steroids) within 14 days of study registration
Allergy to Brussels sprouts

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of MinnesotaMinneapolis, Minnesota

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 17, 2023. Always confirm current availability with the study team.

View original record ↗